Tirzepatide, with its dual agonism of GLP-1 and GIP receptors, further amplifies these benefits
This common concern affects many patients considering or currently using GLP-1 receptor agonists like semaglutide (Wegovy) and tirzepatide (Zepbound)
92 NAFLD frequently progresses to nonalcoholic steatohepatitis (NASH), which is a result of prolonged inflammation and hepatocyte damage, ultimately causing fibrosis, HCC, and even death
This model now spans both major GLP-1 manufacturers: Ro serves as a distribution front-end for Novo Nordisk's injectable and oral Wegovy programs and for Eli Lilly's Zepbound and Foundayo, allowing Ro to offer branded drugs from both manufacturers without taking on inventory or regulatory complexity
They use a minimal dosage of 25 milligrams per serving across all products, making it easy to switch from an edible to an oil
At Centra Internal Medicine, we understand that testosterone replacement therapy (TRT) is a valuable option for individuals diagnosed with clinically low testosterone levels